Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Carboplatin + Niraparib + Paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Niraparib||Zejula||MK4827||PARP Inhibitor (Pan) 25||Zejula (niraparib) binds and inhibits PARP, which may result in accumulation of DNA damage and apoptosis of tumor cells (PMID: 23810788). Zejula (niraparib) is FDA-approved as maintenance therapy in patients with recurrent or newly-diagnosed epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy, and in ovarian, fallopian tube, or primary peritoneal cancer that received 3 or more chemotherapies and is homologous recombination deficient as indicated by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and progressed 6 months or more after response to last platinum-based chemotherapy (FDA.gov).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 13 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05183984||Phase II||Carboplatin + Niraparib + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Niraparib||Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer (NIRVANA-1)||Recruiting||FRA||0|
|NCT05009082||Phase III||Carboplatin + Niraparib + Paclitaxel Bevacizumab + Niraparib Bevacizumab + Carboplatin + Paclitaxel||Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer||Not yet recruiting||0|
|NCT04159155||Phase II||Carboplatin + Cisplatin + Paclitaxel Carboplatin + Niraparib + Paclitaxel Carboplatin + Paclitaxel||A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer (CAN-STAMP)||Recruiting||CAN||0|
|NCT04762901||Phase I||Cyclophosphamide + Doxorubicin + Niraparib + Pegfilgrastim Cyclophosphamide + Doxorubicin + Niraparib Niraparib + Paclitaxel Carboplatin + Niraparib + Paclitaxel||LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer||Withdrawn||0|